News

PolyU Research Centre for SHARP Vision collaborates with Ho Chi Minh City Eye Hospital to develop national guidelines for myopia management in children

The PolyU Research Centre for SHARP Vision (RCSV) has entered into partnership with the Ho Chi Minh City Eye Hospital, Vietnam, to jointly address the increasing prevalence of myopia among Vietnamese children and adolescents.  The international collaboration aims to develop the National Myopia Management Guidelines for Children, which sets out evidence-based strategies for the prevention, early detection, and treatment of childhood myopia, with a view to ensuring a healthier future for Vietnam’s younger generations.   A consensus meeting was held in Ho Chi Minh City on 9 September 2025, bringing together a distinguished group of healthcare professionals, researchers, policymakers, and representatives from leading NGOs to witness the significant milestone.  At the meeting, experts explored critical areas in childhood myopia management to be addressed in the comprehensive guidelines, including advanced interventions to slow myopia progression, early detection and screening for at-risk children, and evidence-based prevention strategies.  In addition, Prof. HE Mingguang, Director of RCSV, Chair Professor of Experimental Ophthalmology and Henry G. Leong Professor in Elderly Vision Health, and Dr Le Anh TUAN, Director of Ho Chi Minh City Eye Hospital, signed an Memorandum of Understanding, marking the two sides’ commitment to fostering international collaboration to advance child eye health. The development of the National Myopia Management Consensus Guidelines for Children is a collaborative effort led by Ho Chi Minh City Eye Hospital, the Vietnam National Institute of Ophthalmology, and the Vietnam Ophthalmological Society, in partnership with RCSV.  The initiative also benefited from the participation of international experts from PolyU and The Chinese University of Hong Kong. The initiative aims to: Standardise clinical practices for myopia management, ensuring consistent, high-quality care across Vietnam. Promote school and community-based health policies to detect and prevent myopia in children. Enhance training and knowledge-sharing for healthcare professionals to implement the latest evidence-based treatments. Foster international cooperation to exchange expertise, resources, and research for long-term impact. This collaboration highlights Vietnam’s dedication to leveraging international expertise and evidence-based practices to address the growing public health challenge of myopia.  By prioritising prevention and early intervention, the guidelines aim to significantly improve children’s vision and overall quality of life.  RCSV will continue to create knowledge and solutions for the promotion of healthy life-long sharp vision.

Prof. HE Mingguang featured in video interview on pioneering ophthalmology technologies

Prof. HE Mingguang, Director of Research Centre for SHARP Vision (RCSV), Chair Professor of Experimental Ophthalmology and Henry G. Leong Professor in Elderly Vision Health, was interviewed by The 21st Century Business Herald to share his research journey in ophthalmology, and introduce his two distinguished studies including the AI-powered portable, self-testing retinal fundus camera for diabetic retinopathy screening, and the use of repeated low-level red-light therapy to reduce the prevalence of myopia in children.   Online coverage: The 21st Century Business Herald - https://polyu.me/4dzgzNT Sina - https://polyu.me/4j6mLhj

Prof. HE Mingguang featured in Wen Wei Po on pioneering ophthalmology technologies

Prof. HE Mingguang, Director of Research Centre for SHARP Vision (RCSV), Chair Professor of Experimental Ophthalmology and Henry G. Leong Professor in Elderly Vision Health, was interviewed by Wen Wei Po to discuss two ground-breaking studies he leads. Both projects, recognised as world-leading innovations, have secured multiple patents.     Among his innovations is the AI-powered, portable retinal fundus camera designed for self-testing screening for diabetic eye. This device enables efficient, comprehensive and accurate screening without requiring trained technicians. It automatically targets the subject’s eyes to capture fundus images within one minute without pupil-dilation or fluorescein injection. After this, the device transmits the image to an AI system, which assesses the optic nerve, fundus in both eyes, and detects signs of glaucoma, diabetic retinopathy or cataract, without requiring interpretation from medical professionals. The research team has collaborated with OPTICAL 88 to install these devices in designated stores for public use.     For myopia management, Prof. He’s team developed a non-invasive repeated low-level red-light (RLRL) therapy to reduce the progression of childhood myopia. The team has recently improved the treatment by reducing light intensity, shortening treatment duration and optimising the illumination system. The therapy can halt myopia progression and even reduce the degree of myopia. Research showed that individuals with high myopia have their prescription reduced from 500 to 450 degrees after the treatment. This advancement offers a breakthrough solution to manage the global rise of myopia among children.     The two innovations underscore Prof. He’s commitment to transforming eye care through accessible, cutting-edge technologies.     Online coverage: Wen Wei Po - https://polyu.me/4l5I8kX; https://polyu.me/4j89lSl; https://polyu.me/3XxeNpy

PolyU-developed High-Definition Corneal Topographer to be showcased at Consumer Electronics Show in Las Vegas

Prof. KEE Chea-su, Associate Director of the Research Centre for SHARP Vision (RCSV), Head and Professor of the School of Optometry and Co-founder of GOOD Vision Technologies Co., Ltd, introduced the world’s first portable High-Definition Corneal Topographer “K-Shape” developed by his team in an interview with TVB. The innovation leverages AI-driven algorithms to accurately measure corneal power, provide early diagnosis of vision problems such as corneal astigmatism and corneal ectasia, and simplify the diagnosis process, enabling it to be completed in as little as one minute. The device will be showcased at the Consumer Electronics Show 2025 to be held in Las Vegas, USA, in January 2025.   Online coverage: TVB - https://polyu.me/3ZHECU4 (00:44 - 01:13) Wha Tech - https://polyu.me/3ZAY8BG

RCSV partners with industry to explore Naked-Eye 3-Dimensional Vision Training for myopia control

The partnership between The Hong Kong Polytechnic University (PolyU) and Holo See Medical Technology (Shenzhen) Co., Ltd marks a significant step forward in the application of naked-eye 3D technology in the medical field, particularly in addressing visual health issues like myopia. This collaboration aims to leverage PolyU's leading research in optometry and myopia control, alongside Holo See's technological expertise, to develop innovative solutions for myopia prevention and treatment. An agreement signing cum inauguration ceremony for this collaboration was held on 9 December 2024. The agreement was signed by Prof. HE Mingguang, Director of Research Centre for SHARP Vision of PolyU, and Mr YANG Keqing, Director of Holo See Medical Technology (Shenzhen) Co., Ltd, under the witness of PolyU representative Prof. CHEN Qingyan, Director of PolyU Academy for Interdisciplinary Research, and Holo See representative, Ms HONG Wanjun, Managing Director of Holo See Medical Technology (Shenzhen) Co., Ltd. The ceremony was also attended by Mr LIU Xiao, Director of Doctorglasses China Co., Ltd and Mr ZHU Wui, Director of Shenzhen Jinghu Investment Consulting Co., Ltd. At the ceremony, Prof. Chen mentioned myopia is a widespread epidemic globally and has created a significant social burden. PolyU has continuously conducted research on myopia, and this collaboration with Holo See aims to further promote the university's research findings on myopia to the broader community. Prof. He also expressed enthusiasm for exploring the potential of naked-eye 3D stereoscopic vision training technology in myopia prevention and other visual health applications. Mr Yang acknowledged PolyU's top ranking in optometry and its significant contributions to myopia control, expressing optimism for a fruitful collaboration that could lead to groundbreaking advancements in the field. This partnership is poised to enhance the understanding and management of myopia, benefiting both the academic community and the general public.

RCSV Members Recognised as Top Two Percent Scientists Worldwide

RCSV is very pleased to announce that nine members are on the Stanford University’s list that represents the top two percent of the most-cited scientists in various disciplines. The report was prepared by a team of experts led by Prof. John Ioannidis, Professor of Medicine (Stanford Prevention Research) of Epidemiology and Population Health at the Stanford University.   Prof. Chen Xiaojun Prof. Benny Cheung Prof. He Mingguang Prof. Marco Pang Prof. Wong Man-sau Prof. Maurice Yap Prof. Yip Shea-ping Prof. Jane YOU  Ir Prof. Zheng Yongping The list issued by the Stanford University can be downloaded from the link below: https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/7   Congratulations to our top scientists!

RCSV Associate Director was Elected as a Fellow of the International Academy for Production Engineering (CIRP)

RCSV congratulated Prof. Benny Cheung, Associate Director of RCSV, on being elected as a Fellow of the International Academy for Production Engineering (CIRP) on 24 August 2024.  CIRP (https://www.cirp.net/) is the world leading organization in production engineering research. This distinguished honor recognizes Prof. Cheung's unwavering dedication to fostering international scientific research and collaboration on production engineering. Currently, Prof. Cheung is the only Fellow member of the Academy at Hong Kong, China. We extend our heartiest congratulations to Prof. Cheung on this remarkable achievement.   

PolyU collaborates with HKI Biotechnology to establish joint laboratory for biotech innovation

The Hong Kong Polytechnic University (PolyU) has entered into a formal collaboration with HKI Biotechnology Limited to foster biotechnology research, with the aim of driving biotech innovations to contribute to the development of drugs and treatments for ophthalmic and systemic diseases. An agreement signing cum inauguration ceremony for the establishment of the “PolyU–HuiKang Joint Laboratory for Biotech Innovation” was held on 16 July 2024. The agreement was signed by Prof. Christopher CHAO, Vice President (Research and Innovation) of PolyU, and Mr SUN Jian, Director of HKI Biotechnology Limited, under the witness of PolyU representatives including Prof. CHEN Qingyan, Director of PolyU Academy for Interdisciplinary Research; Prof. KEE Chea-su, Head and Professor of School of Optometry; Prof. He Mingguang, Director of Research Centre for SHARP Vision, and HuiKang representatives including Mr ZHANG Xiaoqi, Vice President; Mr LI Yuan, General Manager of R&D Business Department; and Ms CHENG Yunlong, Chief Financial Officer. The ceremony was also attended by Mr Victor ZHAO, Associate Director of Research Innovation Office of PolyU; Dr GE Ming, Commissioner for Industry (Innovation and Technology) of Innovation, Technology and Industry Bureau, HKSAR; and Mr ZHANG Keke, Advisor of Shenzhen–Hong Kong–Macau Science and Technology Alliance and Former Vice Chairman of Shenzhen Association for Science and Technology. At the ceremony, Prof. Christopher Chao said that this university-industry research collaboration would combine PolyU’s research strengths in life science and engineering, and HuiKang’s industrial expertise in peptide technology and drug development to open up new directions for target discovery and drug development. Under the agreement, the two parties will conduct collaborative research projects, share research facilities and equipment, promote knowledge exchange and develop research talents. The Joint Laboratory will be operated by the Research Centre for SHARP Vision of PolyU and HKI Biotechnology Limited. It will focus on research on “Peptide Screening and Application Solutions” with the goal of advancing peptide drug discovery and enhancing high-throughput screening technologies. It will also focus on the transformation of outcomes from projects on “Human Lysozyme Eye Drops” into novel pharmaceuticals.

RCSV Member appointed as Non-official Member of Primary Healthcare Committee

RCSV congratulated Prof. Marco Pang, RCSV Member, Shun Hing Education and Charity Fund Professor in Rehabilitation Sciences, Chair Professor of Neurorehabilitation, and Head of the Department of Rehabilitation Sciences, for being appointed as a Non-official Member of the Primary Healthcare Committee of the HKSAR Government for a term of two years, effective from 15 July 2024. The Committee advises the newly established Primary Health Commission on the planning of primary healthcare services and the allocation of resources through strategic purchasing, with the goal of enhancing the overall primary healthcare service.   HKSAR Government Press Release: https://www.info.gov.hk/gia/general/202407/15/P2024071500326.htm?fontSize=1  

RCSV Director shares with Nature on repeated low-level red-light therapy for myopia control in children

Prof. He Mingguang, Director of RCSV, was interviewed by the journal Nature on his study about using repeated low-level red-light (RLRL) therapy to reduce the prevalence of myopia in children. Prof. He and his collaborators conducted a year-long study at ten primary schools in Shanghai. Results showed that children at risk of developing myopia (premyopia) who received the RLRL therapy for three minutes twice per day, five days per week, were half as likely to develop myopia than children who did not receive the therapy, demonstrating the promising application of RLRL therapy for controlling and preventing myopia.   Online coverage: Nature - https://polyu.me/4bH1ojO NetEase - https://polyu.me/3Kp6ODR (Chinese only)